Alnylam Pharmaceuticals (ALNY) reported second-quarter 2024 adjusted earnings of 56 cents per share against the Zacks Consensus Estimate of a loss of 74 cents. The improvement was primarily driven by the recognition of a payment of approximately $185 million, which was previously deferred, upon modifying Alnylam’s ongoing collaboration with Regeneron (REGN) . The company had incurred a loss of $1.62 per share in the year-ago quarter.The adjusted figure excluded items like stock-based compensation expenses a ...